Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

David Arterburn, Lesley H. Curtis, Sengwee Toh, Marie C. Bradley, David D’Alessio, Noelia Duchovny, David Hines, Kimberly Narain, Anand Parekh, Asheley Skinner, Christina C. Wee, John B. Wong, Davene R. Wright, Stavroula K. Osganian, Craig Hales

Open source

DOI: 10.7326/annals-25-05468
Published: 2026-09
Container: Annals of Internal Medicine
Publisher: American College of Physicians
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.7326/annals-25-05468,
  title = {Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop},
  author = {David Arterburn and Lesley H. Curtis and Sengwee Toh and Marie C. Bradley and David D’Alessio and Noelia Duchovny and David Hines and Kimberly Narain and Anand Parekh and Asheley Skinner and Christina C. Wee and John B. Wong and Davene R. Wright and Stavroula K. Osganian and Craig Hales},
  year = {2026},
  journal = {Annals of Internal Medicine},
  doi = {10.7326/annals-25-05468},
  url = {https://doi.org/10.7326/annals-25-05468}
}

RIS

TY  - JOUR
TI  - Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop
AU  - David Arterburn
AU  - Lesley H. Curtis
AU  - Sengwee Toh
AU  - Marie C. Bradley
AU  - David D’Alessio
AU  - Noelia Duchovny
AU  - David Hines
AU  - Kimberly Narain
AU  - Anand Parekh
AU  - Asheley Skinner
AU  - Christina C. Wee
AU  - John B. Wong
AU  - Davene R. Wright
AU  - Stavroula K. Osganian
AU  - Craig Hales
PY  - 2026
JO  - Annals of Internal Medicine
DO  - 10.7326/annals-25-05468
UR  - https://doi.org/10.7326/annals-25-05468
ER  -

APA

Arterburn, D., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D., Narain, K., Parekh, A., Skinner, A., Wee, C. C., Wong, J. B., Wright, D. R., Osganian, S. K., & Hales, C. (2026). Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-05468

Source records

crossref · retrieved 2026-09-26T13:30:33.795Z